Phosphagenics' transdermal carrier successfully delivered insulin in animal model

By Lisa Kerner

Erie, Pa., May 25 - Results from a preclinical trial of transdermal insulin delivery technology indicate that Phosphagenics Ltd.'s transdermal carrier, TPM-02, successfully delivered insulin through the skin of non-diabetic pigs.

The pigs were fasted overnight prior to receiving a continuous infusion of dextrose (a form of glucose) 30 minutes after TPM-02/insulin was applied to the animals' skin, according to a news release.

Phosphagenics said the six pigs that received TPM-02/insulin had significantly lower blood glucose levels than the control group of seven pigs.

"The study has successfully demonstrated the ability of TMP-02/insulin to deliver insulin across the skin of pigs at levels sufficient to lower glucose in the blood," principal investigator Frank Dunshea said in the release.

The non-diabetic pig model is considered to be robust for both testing the penetration of drugs across skin as well as for determining the efficacy of diabetes therapies, the company said.

A similar glucose tolerance study was carried out in rats in September 2005.

Phosphagenics plans a human phase 1 study in healthy volunteers in the third quarter.

The annual world market for insulin is about $5.5 billion.

Phosphagenics is a pharmaceutical and nutraceutical company based in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.